Efficacy, safety and differential outcomes of immune-chemotherapy with gemcitabine, cisplatin and durvalumab in patients with biliary tract cancers: A multicenter real world cohort.

ABSTRACT:

Background

Combined Immuno-chemotherapy consisting of gemcitabine, cisplatin and the programmed death-ligand one inhibitor durvalumab (GCD) is the new standard of care for patients with biliary tract cancers (BTC) based on positive results of the TOPAZ-1 study.

Objective

We here evaluated the efficacy and safety of GCD for BTC in a German multicenter real-world patient cohort.

Methods

Patients with BTC treated with GCD from 9 German centers were included. Clinicopathological baseline parameters, overall survival (OS), response rate and adverse events (AEs) were retrospectively analyzed. The prognostic impact was determined by Kaplan-Meier analyses and Cox regression models.

Results

A total of 165 patients treated with GCD between 2021 and 2024 were included in

SUBMITTER: Mitzlaff K 

PROVIDER: S-EPMC11578849 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature